gavi.org
GOVERNANCE COMMITTEE CHAIR REPORT
BOARD MEETING
Sarah Goulding
7 -8 December 2022, Geneva, Switzerland
Routine (Recurring) Work
? Board and Committee nominations, including Committee Leadership
? Recruitment of Unaffiliated Board Members (GC Subcommittee)
? Monitoring of application of Guiding Principles on Gender for Board and Committee
nominations
? Monitoring of Governance Risk Matrix
2 Board Meeting, 7 -8 December 2022

gavi.org
INVESTMENT COMMITTEE
CHAIR REPORT
BOARD MEETING
Afsaneh Beschloss
7 -8 December 2022, Geneva, Switzerland
Easy Monetary Policy Inflated Asset Prices
2 Board Meeting, 7 -8 December 2022
1Q
2022
2Q
2022
3Q
2022
4Q
2022
1Q
2023
Bloomberg Data Monthly as of 09 Nov 2022
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
0
5
10
15
20
25
30
35
40
Balance Sheet (USD Trillions)
Central Bank Balance Sheet Versus S&P 500
Fed ECB China Japan S&P 500

gavi.org
IFFIM CHAIR REPORT
BOARD MEETING
Kenneth Lay
7 -8 December 2022, Geneva, Switzerland
IFFIm contribution to Gavi?s funding requirements
? In the period 2016 -2020 (Gavi 4.0), IFFIm contributed US$ 872 million to Gavi
? In the 2021 -2025 period (Gavi 5.0), IFFIm has the capacity to provide US$ 3.4 billion
? US$ 2.5 billion for core funding
? US$ 975 million for COVAX AMC
? Disbursements for Gavi 5.0 as of end August 2022 are US$ 1.2 billion
? US$ 957 million for core funding
? US$ 209 million for COVAX AMC
? IFFIm has provided 17 % of Gavi resources to countries since 2006
2 Board Meeting, 7 -8 December 2022

PPC Meeting, 31 October - 1 November 2022
Discussion, Information and Guidance Items
? CEO Report
? COVAX ? Key Strategic Issues
2 Board Meeting, 7 -8 December 2022
PPC Meeting, 31 October - 1 November 2022
Recommendations to the Board
? Human papillomavirus (HPV) Vaccine Programme ( Agenda Item 7 )
? Gavi?s role in support to Regional and African Vaccine Manufacturing ( Agenda Item 8 )
? Gavi?s role in a future COVID -19 Vaccine Programme ( Agenda Item 10 )
? Funding Policy Review ( Agenda Item 11 )
? Gavi Support for Inactivated Poliovirus Vaccine ( Consent Agenda )
3 Board Meeting, 7 -8 December 2022

gavi.org
FUNDING POLICY REVIEW
BOARD MEETING
Marta Tufet, Emmanuel Bor
7 -8 December, Geneva, Switzerland
The Framework on Gavi Funding to Countries offers a
narrative of the three policies' principles and interactions
Co -financing Policy
Vaccine procurement:
rules, safeguards and exceptions
Eligibility and Transition Policy
Sustainable progress:
readiness, criteria and phases
HSIS Policy
Sustainable and equitable immunisation,
system -wide support
Funding Policy
Framework
Overarching narrative
document that outlines
the key principles and
interactions between
the three policies
Board Meeting, 7 -8 December 2022

gavi.org
REPORT FROM AUDIT AND INVESTIGATIONS
BOARD MEETING
Lucy Elliott
7 -8 December 2022, Geneva, Switzerland
Audit and Finance Committee -approved work
plan of country - and secretariat -focused audits
Identification of misuse
Preventive counter -fraud work
Confidential whistle -blower reporting
Investigative activity
How has A&I fulfilled its Terms of Reference in 2022?
Overseen, reviewed and monitored by the Audit and Finance Committee
2 Board Meeting, 7 -8 December 2022
? Recommendations for improvement in
governance, risk management and control
? Enhanced accountability
? US$ 44.5 million identified since 2009
? US$ 38.1 million repaid as at the last report to
the Audit and Finance Committee
? Objective is 100% recovery
? Fraud risk assessment
? Appropriate treatment of reports
? Accountability

gavi.org
AUDIT AND FINANCE COMMITTEE CHAIR REPORT
ANNEX A: REVIEW OF DECISIONS
BOARD MEETING
Naguib Kheraj
7-8 December 2022 , Geneva, Switzerland
Decision 1: Risk Management update (incl. Risk and
Assurance Report)
The Gavi Alliance Audit and Finance Committee recommended to the Gavi Alliance Board that it:
? Approve the Draft Risk & Assurance Report 2022 as set out in Annex A of Doc 04 , as amended by
revisions as requested by the AFC .
2 Audit and Finance Committee Meeting, 19 October 2022

gavi.org
EVALUATION ADVISORY
COMMITTEE CHAIR REPORT
BOARD MEETING
James Hargreaves
7 -8 December 2022, Geneva,
Switzerland
Overview: Gavi 5.0 multi - year evaluation workplan
2 Board Meeting, 7 -8 December 2022

gavi.org
GAVI?S ROLE IN SUPPORT TO REGIONAL AND AFRICAN
VACCINE MANUFACTURING
BOARD MEETING
Dominic Hein, David Kinder
7 -8 December 2022, Geneva, Switzerland
The African region, while having significant demand for vaccines,
currently has limited regional manufacturing
2 Board Meeting, 7 -8 December 2022
Figure: Supply of WHO pre -qualified vaccines in 2021
Source: WHO, Linksbridge
? Limited regional manufacturing, particularly in
Africa, may have contributed to delays in
equitable vaccine access during C -19 pandemic
? This highlighted that supply security is not
always guaranteed
? Desire from many African countries to increase
local capacity ? for both pandemic response and
routine / interpandemic vaccines
? Broad support from international community
? Gavi has opportunity to support given market
shaping experience & large volumes procured
? Gavi?s contribution will have a downstream focus
that synergises with actors upstream

gavi.org
COVAX: KEY STRATEGIC ISSUES
BOARD MEETING
Thabani Maphosa, Derrick Sim
7 -8 December 2022, Geneva, Switzerland
Population
Focus
Progression from COVAX in 2022 -2023 to Gavi -supported COVID -19
programme from 2024
Today: COVAX in transition 2024 onwards: Potential Gavi supported C19 Programme
Increasing focus on higher
priority user groups, incl.
additional boosters
Continued support across all
user groups for primary + 1,
esp. for low coverage countries
Transition to support higher priority user groups
Additional doses/ newer products via
PVP for worst case scenario
Reactive strategy for worst case scenario
ILLUSTRATIVE
Board Meeting, 7 ?8 December 2022

Classified as Internal
gavi.org
GAVI?S ROLE IN A FUTURE
COVID -19 VACCINE PROGRAMME
BOARD MEETING
Derrick Sim, Richard Mihigo
7 -8 December 2022, Geneva, Switzerland
Classified as Internal
Why should Gavi support a future COVID - 19 programme ?
2
Shift from an
emergency
response focused
on global health
security to
protection of the
most vulnerable ,
while retaining ability
to quickly mobilise in
a worst -case
scenario
Strategic
Objective
Board Meeting, 7 ?8 December 2022
Impact to date...
Recent modelling estimates that COVAX -supported COVID -19 doses have
averted over 1.7 million deaths across AMC participants
AMCs look to COVAX to supply a large proportion of their COVID -19 doses
? with LICs relying on COVAX for ~75% of their supply ? providing
continued access critical for global fight against COVID -19
Current epidemiology...
Initial impact projections show deaths averted per fully vaccinated person ,
especially for higher -risk populations, are in the same range as those of other
Gavi -supported vaccine programmes
Looking ahead...
A COVID -19 programme can support and strengthen platforms for life -course
vaccination and contribute to learnings on integration of immunisation into
primary health care in view of Gavi 6.0
Many regions are experiencing a surge as several variants continue to co -
circulate . Some countries are experiencing their highest ever incidence,
although vaccination has helped reduce severe disease and death .